Treatment strategies for highly treatment-experienced HIV-infected patients

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 5, 2005, Pages 815-823

  Luber, Andrew D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiretroviral; HIV; Protease inhibitor; Resistance; Tipranavir

Indexed keywords

AMPRENAVIR; AMPRENAVIR PLUS LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR PLUS SAQUINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG UPTAKE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; IC 50; IN VITRO STUDY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; MUTATIONAL ANALYSIS; REVIEW; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 27544489336     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.5.815     Document Type: Review

References (37)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860 (1998).
2. Mellors J. New insights into mechanisms of HIV-1 resistance to reverse transcriptase inhibitors. Presented at the 9th Conference on Retroviruses and Opportunistic Infections MA, USA (2002).
3. Soriano V, de Mendoza C. Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin. Trials 3, 237-248 (2002).
4. Clumeck N, Brun S, Sylte J et al. Kaletra (ABT-378/r) and efavirenz: one-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. IL, USA (2001).
5. Kempf DJ, Isaacson JD, King MS et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7, 165-174 (2002).
6. Hsu A, Isaacson J, Brun S et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47, 350-359 (2003).
7. Hsu A, Granneman G, Kempf D et al. The Ctrough inhibitory quotient predicts virologic response to ABT-378/ritonavir (ABT-378/r) therapy in treatment-experienced patients. AIDS 14(Suppl. 4), S12 (2000).
8. Podzamczer D, Tressler R, Flexner C et al. Higher doses of lopinavir/ritonavir (LPV/r) in highly treatment-experienced, HIV-infected patients: 48-week safety/efficacy evaluation. Presented at the 15th International AIDS Conference. Bangkok, Thailand (2004).
9. Bertz R, Li J, King M et al. Lopinavir inhibitory quotient predicts virologic response in highly antiretroviral-experienced patients receiving high-dose lopinavir/ritonavir. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. CA, USA (2004).
10. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9, 1051-1053 (1993).
11. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV Infection in North and South America. N. Engl. J. Med. 348, 2175-2185 (2003).
12. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348, 2186-2195 (2003).
13. Katlama C, Arastéh K, Clotet B et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France (2003).
14. Montaner J, DeMasi R, Delehanty J et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management. Antivir. Ther. 8(Suppl. 1), S212 (2003).
15. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J. Acquir. Immune Defic. Syndr. 34(Suppl. 1), S91-S94 (2003).
16. Schake D. How flexible is tipranavir in complex with the HIV-1 protease active site? AIDS 18, 579-580 (2004).
17. Walmsley S, Leith J, Katlama C et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir: interim analysis of BI 1182.51. Presented at the 15th International AIDS Conference. Bangkok, Thailand (2004).
18. Hicks C. RESIST-1: a Phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral-experienced patients: 24-week data. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004).
19. Cahn P. 24-week data from RESIST 2: phase 3 study of the efficacy and safety of either tipranavir/ritonavif (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV+ patients. Proceedings of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2004).
20. Shulman NS, Bosch RJ, Mellors JW. Albrecht MA, Katzenstein DA. Genetic correlates of efavirenz hypersusceptibility. AIDS 18, 1781-1785 (2004).
21. Demeter L, DeGruttola V, Lustgarten S et al. A genotypic score for efavirenz hypersusceptibility is associated with virologic response to EFV + indinavir ± abacavir in nucleoside-experienced patients. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. CA, USA (2004).
22. Haubrich RH, Kemper CA, Hellmann NS et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospect cohort analysis. AIDS 16, F33-F40 (2002).
23. Staszewski S, Dauer B, von Hentig N et al. The LOPSAQ study: 24 week analysis of the double protease inhibitor salvage regimen containing lopinavir (LPV/r) plus saquinavir without any additional antiretroviral (ART) therapy. Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France (2003).
24. Staszewski S, Dauer B, Carlebach A et al. The LOPSAQ salvage study: 48 week analysis of the full cohort treated with lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy. Program and abstracts of the XV International AIDS Conference (2004).
25. Dam E, Rochas S, Faudon JL et al. Synergistic activity of lopinavir and saquinavir on protease inhibitor-resistant HIV-1. Presented at the 11th Conference of Retroviruses and Opportunistic Infections. CA, USA (2004).
26. Molla A, Mo H, Vasavanonda S et al. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob. Agents Chemother. 46, 2249-2253 (2002).
27. Montaner JSG, Harrigan PR, Jahnke N et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 15, 61-69 (2001).
28. Haubrich RH. Resistance and replication capacity assays: clinical utility and interpretation. Top. HIV Med. 12, 52-56 (2004).
29. Barbour JD, Wrin T, Hecht FM et al. Wide variation in Pro/Pol replication capacity in recently transmitted HIV-1 is conferred in part by protease inhibitor resistance mutations. Antivir. Ther. 8, S80 (2003).
30. Barbour JD, Wrin T, Grant RM et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76, 11104-11112 (2002).
31. Lawrence J, Mayers DL, Hullsiek KH et al. Structured treatment interruption in patients with multi-drug resistant human immunodeficiency virus. N. Engl. J. Med. 349, 837-846 (2003).
32. Katlama C, Dominguez S, Gourlain K et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18, 217-226 (2004).
33. Hirsch MS, Brun-Vezinet F, Bonaventura C et al. Antiretroviral drug resistance testing in adults infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society - USA Panel. Clin. Infect. Dis. 37, 113-128 (2003).
34. Johnson VA, Brun-Vezinet F, Bonaventura C et al. Update of the drug resistance mutations in HIV-1: 2005. Top. HIV Med. 13, 51-57 (2005).
35. de Mendoza C, Martin-Carbonero L, Gallego O et al. Relationship between drug resistance mutations, plasma viremia, and CD4 T-cell counts in patients with chronic HIV infection. J. Med. Virol. 76, 1-6 (2005).
36. Raffanti S, Fusco JS, Sherril BH et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J. Acquir. Immune Defic. Syndr. 37, 1147-1154 (2004).
37. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364, 51-62 (2004).